In today's Pharmaceutical Executive Daily, Parabilis Medicines prices a record-breaking $670 million IPO, Swedish biotech ...
In today's Pharmaceutical Executive Daily, a pharma funding roundup covers two RNA-focused biotechs that secured fresh ...
We have entered a new era, with artificial intelligence (AI) driving one of the fastest technological transformations in ...
Parabilis raised $670M via 33.5M shares at $20 and secured $75M Regeneron private placement at $18, totaling ~$745M gross proceeds ahead of Nasdaq listing. Helicon discovery platform engineers ...
AlzeCure Pharma has licensed Alzheimer's candidate ACD680 to Eli Lilly in a deal worth potentially more than $1 billion, adding an oral gamma-secretase modulator that targets amyloid production ...
Bexobrutideg leverages targeted protein degradation to eliminate BTK, potentially overcoming resistance mutations and ...
Transaction terms include a $124/share all-cash tender offer, implying a 40% premium to prior close, with expected Q3 2026 closing pending antitrust and customary conditions. Regulatory timelines ...
The ACCESS Model’s significance for the industry is that it introduces a new level of operational capacity to what remains ...
Contributing factors include genetic predisposition, stress, nutritional deficiencies, autoimmune or thyroid disorders, ...
City Therapeutics’ Series B syndicate added Viking Global and Sofinnova, with continued support from multiple crossover and strategic investors, signaling broad buy-side confidence in RNAi platform ...
Under the terms of the agreement, Alnylam will provide $30 million in upfront consideration, including cash and an equity ...
AstraZeneca ($18.5B), BMS ($15.2B), and Pfizer ($10.5B) anchored early-2026 China partnering, reflecting a structural shift from ~5% of licensing four years ago to a majority today. China dealmaking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results